Publications Supported by the DOVE Project

Publications Supported by the DOVE ProjectPublished on DOVE: Stop Cholera (https://www.stopcholera.org)

Publications Supported by the DOVE Project

1. Abubakar A, Azman AS, Rumunu J, et al. The First Use of the Global Oral Cholera VaccineEmergency Stockpile: Lessons from South Sudan [1]. PLoS Med 2015; 12(11): e1001901.

2. Aibana O, Franke MF, Teng JE, Hilaire J, Raymond M, Ivers LC. Cholera vaccination campaigncontributes to improved knowledge regarding cholera and improved practice relevant towaterborne disease in rural Haiti [2]. PLoS Negl Trop Dis 2013; 7(11): e2576.

3. Ali M, Debes AK, Luquero FJ, et al. Potential for Controlling Cholera Using a Ring VaccinationStrategy: [3]Re-analysis [3] of Data from a Cluster-Randomized Clinical Trial [3]. PLoS Med2016; 13(9): e1002120.

4. Ali, M., Gupta, S., Arora, N., Khasnobis, P., et al. Identification of burden hotspots and riskfactors for cholera in India: An observational study [4]. PLoS One 2017; 12(8): e0183100.

5. Ali, M., Kim, P., Zaman, K., Clemens, J. Herd protection of unvaccinated adults by oral choleravaccines in rural Bangladesh [5]. International Health 2018; ihy085.

6. Ali, M., Nelson, A., Luquero, F., Azman, A., et al. Safety of a killed oral cholera vaccine(Shanchol) in pregnant women in Malawi: an observational cohort study [6]. The LancetInfectious Diseases 2017; 17(5): 538-544.

7. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries [7]. PLoS Negl Trop Dis 2015; 9(6): e0003832.

8. Ali M, You YA, Kanungo S, et al. Assessing different measures of population-level vaccineprotection using a case-control study [8]. Vaccine 2015; 33(48): 6878-83.

9. Ali M, You YA, Sur D, et al. Validity of the estimates of oral cholera vaccine effectivenessderived from the test-negative design [9]. Vaccine 2016; 34(4): 479-85.

10. Anh DD, Lopez AL, Tran HT, et al. Oral cholera vaccine development and use in Vietnam [10].PLoS Med 2014; 11(9): e1001712.

11. Azman AS, Ivers LC, Legros D, Luquero FJ, Mintz ED. Safe water, sanitation, hygiene, and acholera vaccine [11]. The Lancet 2016; 387(10013): 28.

12. Azman AS, Legros D, Lessler J, Luquero FJ, Moore SM. Outbreaks of cholera in the time ofEbola: pre-emptive action needed [12]. The Lancet 2015; 385(9971): 851.

13. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. The Impact of a One-Doseversus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study [13].

of 6

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001901

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001901


PLoS Med 2015; 12(8): e1001867.

14. Azman AS, Parker LA, Rumunu J, et al. Effectiveness of one dose of oral cholera vaccine inresponse to an outbreak: a case-cohort study [14]. The Lancet Glob Health 2016; 4(11):e856-e63.

15. Azman AS, Rumunu J, Abubakar A, et al. Population-Level Effect of Cholera Vaccine onDisplaced Populations, South Sudan, 2014 [15]. Emerg Infect Dis 2016; 22(6): 1067-70.

16. Bi, Q., Ferreras, E., Pezzoli, L., Legros, D., Ivers, L. C., Date, K., et al. Protection againstcholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis[16]. The Lancet Infectious Diseases 2017; 17(10): 1080-1088.

17. Bwire, Godfrey, Ali, M, Sack DA, et al. Identifying cholera" hotspots" in Uganda: An analysis ofcholera surveillance data from 2011 to 2016 [17]. PLoS neglected tropical diseases 11.12 (2017): e0006118.

18. Chakraborty S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test fordetection of Vibrio [18]cholerae [18] O1 and O139 in environmental water [18]. Frontiers inmicrobiology 2013; 4: 320.

19. Ciglenecki, Isa, Azman AS, Rumunu, J, et al. Vaccination against cholera in Juba - Authors'reply [19]. The Lancet Infectious Diseases 2017; 17(5): 480-481.

20. Debes AK, Ali M, Azman AS, Yunus M, Sack DA. Cholera cases cluster in time and space inMatlab, Bangladesh: implications for targeted preventive interventions [20]. InternationalJournal of Epidemiology 2016.

21. Debes AK, Ateudjieu J, Guenou E, et al. Clinical and Environmental Surveillance for Vibrio [21]cholerae [21] in Resource Constrained Areas: Application During a 1-Year Surveillance inthe Far North Region of Cameroon [21]. Am J Trop Med Hyg 2016.

22. Debes AK, Ateudjieu J, Guenou E, et al. Evaluation in Cameroon of a Novel, SimplifiedMethodology to Assist Molecular Microbiological Analysis of V. [22]cholerae [22] inResource-Limited Settings [22]. PLoS Negl Trop Dis 2016; 10(1): e0004307.

23. Deen J, Ali M, Sack D. Methods to assess the impact of mass oral cholera vaccinationcampaigns under real field conditions [23]. PLoS One 2014; 9(2): e88139.

24. Deen J, von Seidlein L, Luquero FJ, et al. The scenario approach for countries considering theaddition of oral cholera vaccination in cholera preparedness and control plans [24]. TheLancet Infect Dis 2016; 16(1): 125-9.

25. Djouma FN, Ateudjieu J, Ram M, et al. Factors Associated with Fatal Outcomes FollowingCholera-Like Syndrome in Far North Region of Cameroon: A Community-Based Survey[25]. Am J Trop Med Hyg 2016; doi:10.4269/ajtmh.16-0300.

of 6


26. Federspiel, F., Ali, M. The cholera outbreak in Yemen: lessons learned and way forward [26]. BMC Public Health 2018; 18:1338.

27. Finger, Flavio, Bertuzzo, Enrico, Luquero, Francisco, et al. The potential impact of case-areatargeted interventions in response to cholera outbreaks: A modeling study [27]. PLoS Med2018; 15(2): e1002509.

28. Hall RH, Sack DA. Introducing cholera vaccination in Asia, [28]Africa [28] and Haiti: Ameeting report [28]. Vaccine 2015; 33(4): 487-92.

29. Ivers LC, Hilaire IJ, Teng JE, et al. Effectiveness of reactive oral cholera vaccination in ruralHaiti: a case-control study and bias-indicator analysis [29]. The Lancet Glob Health 2015;3(3): e162-8.

30. Ivers LC, Teng JE, Lascher J, et al. Use of oral cholera vaccine in Haiti: a rural demonstrationproject [30]. Am J Trop Med Hyg 2013; 89(4): 617-24.

31. Iyer AS, Bouhenia M, Rumunu J, et al. Immune Responses to an Oral Cholera Vaccine inInternally Displaced Persons in South Sudan [31]. Sci Rep 2016; 6: 35742.

32. Khan, A. I., Ali, M., Chowdhury, F., Saha, A., Khan, I. A., Khan, A., et al. Safety of the oralcholera vaccine in pregnancy: Retrospective findings from a subgroup following massvaccination campaign in Dhaka, Bangladesh [32]. Vaccine 2017; 35(11): 1538-1543.

33. Lopez AL, Macasaet LY, Ylade M, Tayag EA, Ali M. Epidemiology of cholera in the Philippines[33]. PLoS Negl Trop Dis 2015; 9(1): e3440.

34. Lopez AL, Deen J, Azman AS, Luquero FJ, Kanungo S, Dutta S, von Seidlein L, SackDA. Immunogenicity and protection from a single dose of internationally available killed oralcholera vaccine: A systematic review and metaanalysis [34]. Clinical InfectiousDiseases 2017; cix1039.

35. Luquero FJ, Sack DA. Effectiveness [35] of oral cholera vaccine in Haiti [35]. The Lancet GlobHealth 2015; 3(3): e120-1.

36. Luquero FJ, Ballard A, Sack DA. Ensuring access to oral cholera vaccine to those who needthem most [36]. Vaccine 2017; 35(3): 411.

37. Martin S, Lopez AL, Bellos A, et al. Post-licensure deployment of oral cholera vaccines: asystematic review [37]. Bulletin of the World Health Organization 2014; 92(12): 881-93.

38. M'bangome M, Pezzoli L, Reeder B, et al. Oral cholera vaccine in cholera prevention andcontrol, Malawi [38]. Bulletin of the World Health Organization 2018; 96(6): 428-435.

39. Parker LA, Rumunu J, Jamet C, et al. Adapting to the global shortage of cholera vaccines:targeted single dose cholera vaccine in response to an outbreak in South Sudan [39]. The

of 6


Lancet Infectious Diseases 2017.

40. Parker LA, Rumunu J, Jamet C, et al. Neighborhood-targeted and case-triggered use of asingle dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage [40].PLoS Neglected Tropical Diseases 2017; 11(6): e0005652.

41. Peak CM, Reilly AL, Azman AS, Buckee CO. Prolonging herd immunity to cholera viavaccination: Accounting for human mobility and waning vaccine effects [41]. PLoS Negl TropDis 2018. 12(2): e0006257.

42. Qadri F, Wierzba TF, Ali M, et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine inBangladesh [42]. N Engl J Med 2016; 374(18): 1723-32.

43. Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in anurban endemic setting in Bangladesh: a cluster [43]randomised [43] open-label trial [43].The Lancet 2015.

44. Sack DA. A new era in the history of cholera: the road to elimination [44]. Int J Epidemiol2013; 42(6): 1537-40.

45. Sack DA, Ali M. Protection from killed oral cholera vaccine continues for 4 years [45]. TheLancet Global Health 2018; 6(9): PE946-E947.

46. Troeger C, Sack DA, Chao DL. Evaluation of targeted mass cholera vaccination strategies inBangladesh: a demonstration of a new cost-effectiveness calculator [46]. Am J Trop Med Hyg2014; 91(6): 1181-9.

47. Von Seidlein, L, Sack, D, Azman, A, et al. Cholera outbreak in Yemen [47]. The LancetGastroenterology & Hepatology 2017; 2(11): 777.

48. Von Seidlein, Lorenz and Deen, Jacqueline. Preventing cholera outbreaks through earlytargeted interventions [48]. PLoS Med 2018; 15(2): e1002510.

49. Yakum MN, Ateudjieu J, Guenou E, Walter EA, et al. Health seeking behaviour amongsuspected cases of cholera in Cameroonian health districts in Lake Chad basin [49]. BMC ResNotes 2017; 10(1): 433.

Source URL: https://www.stopcholera.org/content/publications-supported-dove-project

Links

of 6


[1] http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001901[2] http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002576[3] http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002120[4] http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183100[5] https://academic.oup.com/inthealth/advance-article/doi/10.1093/inthealth/ihy085/5214016[6] http://www.sciencedirect.com/science/article/pii/S1473309916305230[7] http://journals.plos.org/plosntds/article/asset?id=10.1371/journal.pntd.0003832.PDF[8] http://www.sciencedirect.com/science/article/pii/S0264410X15010051[9] http://www.sciencedirect.com/science/article/pii/S0264410X15017764[10] https://www.ncbi.nlm.nih.gov/pubmed/25180511?dopt=AbstractPlus[11] http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01294-5/fulltext[12] http://www.sciencedirect.com/science/article/pii/S0140673615601787[13] http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001867[14]http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(16)30211-X/fulltext?elsca1=etoc[15] http://wwwnc.cdc.gov/eid/article/22/6/15-1592_article[16] http://www.sciencedirect.com/science/article/pii/S1473309917303596[17] http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006118[18] https://www.ncbi.nlm.nih.gov/pubmed/24194737[19] http://www.sciencedirect.com/science/article/pii/S1473309917301846?via%3Dihub[20] http://ije.oxfordjournals.org/content/early/2016/10/25/ije.dyw267.abstract[21] https://www.ncbi.nlm.nih.gov/pubmed/26755564[22] https://www.ncbi.nlm.nih.gov/pubmed/26735969[23] http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0088139[24] http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00298-4/abstract[25] http://www.ajtmh.org/content/early/2016/10/13/ajtmh.16-0300.abstract[26] https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-6227-6[27] http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002509#ack[28] http://www.sciencedirect.com/science/article/pii/S0264410X14015709[29] http://www.sciencedirect.com/science/article/pii/S2214109X14703687[30] http://www.ajtmh.org/content/89/4/617.abstract[31] http://www.nature.com/articles/srep35742[32] http://www.sciencedirect.com/science/article/pii/S0264410X17301603[33] http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003440[34] https://watermark.silverchair.com/cix1039.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAcwwggHIBgkqhkiG9w0BBwagggG5MIIBtQIBADCCAa4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMH9-SJQFNb0UriXdxAgEQgIIBfzPUlF9JGQ3bwOo9q5RcDAbX0-_0RM5bAaydqvLMA2jP1saKpD3CMM9hD9xCTKophCtxaezYWi2LwWCo9g7emhGezfCqlkesI2uWX2E9aVxmCCMxTxbbOnpiBLb26C1YOKY74yewxlLZac06IWP2jyfQN6tJOKWpgBFj7KVf7cDjBPCpKWtwzyv9ECMYq9fQYeTTFNu2GnRs-hM3RFMWP-_dXA7uMLYCZb-Tmk0PurlR7cBfwqLdoNghjHpumuMX3X-oH2H4Z21bX0ZtLoRMgBP3kVT-Dz0adZBP9RxhrIXaT18nUCDqdPbhVW4K8FUQfPvv4APffbskV2kQEyaYw8aYXua93sh5lW_GkhtKSjbwOz2XC5awMJLLAbKICz-xdTer3WTSREW7AyKjJat09nAh0vnD_LO5qgwZvZN-WMsWFeOiDvFd0_HIyfbNn1sKfeuP_G0H_eAHK4QZoJXCOh8eJAz03ambnL7c9i4kXxO5q-u6sMDbornzhMOZlA__[35] http://www.sciencedirect.com/science/article/pii/S2214109X1570015X[36] https://www.ncbi.nlm.nih.gov/pubmed/27916414[37] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264394/[38] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996210/[39] http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30472-8/abstract[40] http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005652[41] http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006257[42] http://www.nejm.org/doi/full/10.1056/NEJMoa1510330#t=articleTop[43] http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61140-0/fulltext?rss=yes[44] http://ije.oxfordjournals.org/content/42/6/1537.full[45] https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30311-5/fulltext[46] http://www.ajtmh.org/content/early/2014/10/02/ajtmh.14-0159.abstract[47] http://www.sciencedirect.com/science/article/pii/S246812531730287X[48] http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002510[49] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577771/

of 6


of 6

Publications Supported by the DOVE Project

Documents

Transcript of Publications Supported by the DOVE Project